Madrigal Pharmaceuticals (MDGL) revenue
Madrigal Pharmaceuticals (MDGL) reported revenue of $958.40M in fiscal 2025 (the year ended December 31, 2025). That is 432.1% higher than the $180.13M of fiscal 2024. Figures as of 18 Nov 2026, 07:38 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Revenue, fiscal 2025
- $958.40M
- Change on fiscal 2024
- +432.1%
- Highest on record
- $958.40Mfiscal 2025
- Lowest on record
- $147.00Kfiscal 2012
- Fiscal years on record
- 32012–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Madrigal Pharmaceuticals revenue, in more detail
Across the 3 fiscal years on record (2012–2025), the highest was $958.40M in fiscal 2025 and the lowest $147.00K in fiscal 2012.
Revenue by fiscal year
Madrigal Pharmaceuticals revenue, year by year
| Fiscal year | Revenue | Change | Year ended |
|---|---|---|---|
| 2025 | $958.40M | 432.1% up | |
| 2024 | $180.13M | — | |
| 2012 | $147.00K | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.
How to read it
Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.
Revenue at health care companies of similar size
| Company | Revenue | Fiscal year |
|---|---|---|
| Qiagen QGEN | $2.09B | 2025 |
| Insulet PODD | $2.71B | 2025 |
| Bruker BRKR | $3.44B | 2025 |
| Globus Medical GMED | $2.94B | 2025 |
| Madrigal Pharmaceuticals MDGL | $958.40M | 2025 |
| Henry Schein HSIC | $13.18B | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Madrigal Pharmaceuticals, figure by figure
- Madrigal Pharmaceuticals market cap
- Madrigal Pharmaceuticals earnings
- Madrigal Pharmaceuticals earnings per share (EPS)
- Madrigal Pharmaceuticals P/E ratio
- Madrigal Pharmaceuticals P/S ratio
- Madrigal Pharmaceuticals P/B ratio
- Madrigal Pharmaceuticals free cash flow
- Madrigal Pharmaceuticals operating margin
- Madrigal Pharmaceuticals dividend
- Madrigal Pharmaceuticals shares outstanding
- Madrigal Pharmaceuticals total debt
- Madrigal Pharmaceuticals cash on hand
- Madrigal Pharmaceuticals total assets
- Madrigal Pharmaceuticals return on equity (ROE)
- Madrigal Pharmaceuticals return on invested capital (ROIC)
Madrigal Pharmaceuticals (MDGL) overview: price, valuation and scorecardAll health care companies by market value
Madrigal Pharmaceuticals revenue: questions and answers
What is Madrigal Pharmaceuticals's revenue?
Madrigal Pharmaceuticals (MDGL) reported revenue of $958.40M in fiscal 2025 (the year ended December 31, 2025). That is 432.1% higher than the $180.13M of fiscal 2024.
What are the highest and lowest revenue figures on record for Madrigal Pharmaceuticals?
Across the 3 fiscal years on record (2012–2025), the highest was $958.40M in fiscal 2025 and the lowest $147.00K in fiscal 2012.
How is Madrigal Pharmaceuticals's revenue calculated?
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.
Fiscal years are named for the calendar year they end in.
Learn: revenue
All stocks guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Madrigal Pharmaceuticals (MDGL) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/MDGL/revenue
Underlying data: the company's filings with the SEC and Yahoo Finance.